Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy …
TE Ciuleanu, S Ahmed, JH Kim, J Mezger… - British journal of …, 2017 - nature.com
Background: Maintenance therapy is important in advanced/metastatic non-small cell lung
cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy …
cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy …
Molecular pathology and personalized medicine: The dawn of a new era in companion diagnostics—practical considerations about companion diagnostics for non …
T Plönes, W Engel-Riedel, E Stoelben… - Journal of Personalized …, 2016 - mdpi.com
Companion diagnostics (CDx) have become a major tool in molecular pathology and assist
in therapy decisions in an increasing number of various cancers. Particularly, the …
in therapy decisions in an increasing number of various cancers. Particularly, the …
Guía de Práctica Clínica Nacional para el manejo del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos
F Barrón-Barrón, E Guzmán-De Alba… - salud pública de …, 2019 - saludpublica.mx
El cáncer de pulmón es una de las principales causas de mortalidad alrededor del mundo.
Su historia natural, con la manifestación de síntomas en etapas avanzadas y el retraso en …
Su historia natural, con la manifestación de síntomas en etapas avanzadas y el retraso en …
Immunotherapy in COVID-19: why, who, and when?
P Sinha, CS Calfee - The Lancet Respiratory Medicine, 2021 - thelancet.com
Nearly 1· 5 years into the global COVID-19 pandemic, immense progress has been made
against SARS-CoV-2 in health care, most prominently in vaccine development. However …
against SARS-CoV-2 in health care, most prominently in vaccine development. However …
[HTML][HTML] Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011–2016
AC Vázquez, PG Flores, AR Ortiz… - Journal of Thoracic …, 2018 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) is a leading cause of death all over the
world. Diagnostic and therapeutic arsenals have improved in recent years, but we are …
world. Diagnostic and therapeutic arsenals have improved in recent years, but we are …
Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung …
L Lin, J Zhao, J Hu, F Huang, J Han, Y He… - OncoTargets and …, 2016 - Taylor & Francis
Purpose Both gefitinib and pemetrexed maintenance were effective therapies for advanced
lung adenocarcinoma, but which is better is unclear. For patients with advanced lung …
lung adenocarcinoma, but which is better is unclear. For patients with advanced lung …
Therapeutic outcomes of autologous CIK cells as a maintenance therapy in the treatment of lung cancer patients: A retrospective study
H Luo, L Gong, B Zhu, Y Huang, C Tang, S Yu… - Biomedicine & …, 2016 - Elsevier
Objective Few clinical studies have confirmed the role of cytokine-induced killer cells (CIKs)
in the maintenance therapy of advanced lung cancer patients. We investigate effectiveness …
in the maintenance therapy of advanced lung cancer patients. We investigate effectiveness …
The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
L Zhang, S Gao, J He - Drug Design, Development and Therapy, 2017 - Taylor & Francis
Purpose Maintenance therapy is an effective treatment strategy for advanced non-small-cell
lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of …
lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of …
[PDF][PDF] Molecular profiling for clinical decision making in advanced cancer: a clinical appraisal
J Capdevila, F Rojo, A González-Martín… - J Cancer Res …, 2017 - academia.edu
In the past five years, technological advances in the field of precision medicine in oncology
have led to the emergence of a number of commercially available services for tumor …
have led to the emergence of a number of commercially available services for tumor …
晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效
马汉宸， 隋东昕， 徐少华 - 山东医药, 2016 - cqvip.com
目的: 探讨晚期肺腺癌患者培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效和
不良反应. 方法选取住院治疗的ⅢB~ Ⅳ 期肺腺癌患者68 例, 随机分为观察组45 例和对照组23 …
不良反应. 方法选取住院治疗的ⅢB~ Ⅳ 期肺腺癌患者68 例, 随机分为观察组45 例和对照组23 …